How Will Wet Seal (WTSL) Stock Be Affected By Its Earnings Results?

NEW YORK (TheStreet) -- Wet Seal (WTSL) announced second quarter revenue of $121.2 million, down from the $137.2 million from the same period last year, and short of the $122.7 million revenue expectations analysts had.

The specialty retailer reported a net loss of 26 cents per diluted share, 14 cents wider that analysts were expecting.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Wet Seal shares are flat in after-hours trading on Wednesday.

TheStreet Ratings team rates WET SEAL INC as a Sell with a ratings score of D-. TheStreet Ratings Team has this to say about their recommendation:

"We rate WET SEAL INC (WTSL) a SELL. This is driven by a number of negative factors, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, disappointing return on equity, poor profit margins, weak operating cash flow and generally disappointing historical performance in the stock itself."

Highlights from the analysis by TheStreet Ratings Team goes as follows:

WTSL Chart WTSL data by YCharts

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

More from Markets

Jim Cramer Live: Breaking Down the Markets and Dave & Buster's

Jim Cramer Live: Breaking Down the Markets and Dave & Buster's

Dow Jumps on Signs of Progress in U.S.-China Trade Discussions

Dow Jumps on Signs of Progress in U.S.-China Trade Discussions

American Eagle Shares Fall After Company Issues Weak Guidance

American Eagle Shares Fall After Company Issues Weak Guidance

Here's Why I Like Adobe Stock Long-Term

Here's Why I Like Adobe Stock Long-Term

Here Are 3 Small-Cap Names for Biotech Investors to Consider

Here Are 3 Small-Cap Names for Biotech Investors to Consider